Synapse - Joachim Yahalom

Results (205)

Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma

Journal Article

Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma

Research Letter

Deschenes-Simard, X.; Pennisi, M.; Perales, M. A.; Shah, G. L.; Zelenetz, A. D.; Yahalom, J.; Imber, B. S.; Santomasso, B. D.; Dahi, P. B.
Leukemia and Lymphoma (2025)

Fulltext@MSK | Save

Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes

Meeting Abstract

Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
Blood (2024)

Fulltext@MSK | Save

Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma

Meeting Abstract

Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
Blood (2024)

Fulltext@MSK | Save

Central nervous system bridging radiotherapy (CNS-BRT) achieves rapid cytoreduction prior to car T-cell therapy for aggressive B-cell lymphomas

Meeting Abstract

Cederquist, G.; Schefflein, J.; Devlin, S.; Shah, G.; Shouval, R.; Hubbeling, H.; Tringale, K.; Fregonese, B.; Hajj, C.; Boardman, A.; more...
Neuro-Oncology (2024)

Fulltext@MSK | Save

A proof-of-principle study of split-course bridging radiotherapy (SC-BRT) prior to commercial CAR T-cell therapies for relapsed or refractory B-cell lymphomas: Results from phase 1a pilot cohort

Meeting Abstract

Imber, B. S.; Palomba, M. L.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K.; Boardman, A.; Dahi, P. B.; Lin, R. J.; Shah, G. L.; more...
International Journal of Radiation Oncology, Biology, Physics (2024)

Fulltext@MSK | Save

Improvement in radiomic features following bridging therapy is prognostic for CD19 chimeric antigen receptor (CAR) T-cell therapy outcome

Meeting Abstract

Hubbeling, H. G.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Boardman, A.; Dahi, P. B.; more...
International Journal of Radiation Oncology, Biology, Physics (2024)

Fulltext@MSK | Save

Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma

Journal Article

Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G.; Fregonese, B.; Wills, B.; Bedmutha, A.; Alarcon Tomas, A.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Research Letter

Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
Blood Cancer Journal (2024)

Fulltext@MSK | Save

CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas

Journal Article

Cederquist, G. Y.; Schefflein, J.; Devlin, S. M.; Shah, G. L.; Shouval, R.; Hubbeling, H.; Tringale, K.; Tomas, A. A.; Fregonese, B.; Hajj, C.; more...
Blood Advances (2024)

Fulltext@MSK | Save